Revvity Analysts Increase Their Forecasts After Q3 Earnings - Revvity ( NYSE:RVTY )
Revvity, Inc. ( NYSE:RVTY ) announced mixed third-quarter 2025 financial results on Monday. Despite adjusted EPS from continuing operations of $1.18, which beat the analyst estimate of $1.14, total revenue of $698.949 million missed the consensus estimate of $700.457 million.
Company News for Oct 28, 2025
Companies In The News Are: ARLP, DQ, KDP, RVTY.
RVTY Q3 Earnings Beat, Sales In Line, '25 EPS View Raised
Revvity beats on Q3 earnings and raises 2025 EPS view, as balanced segment performance offsets margin pressure.
What's Going On With Revvity Stock Monday? - Revvity ( NYSE:RVTY )
Revvity, Inc. ( NYSE:RVTY ) announced its third-quarter 2025 financial results on Monday. The company's performance was mixed compared to analyst expectations, and the stock declined immediately.
Revvity ( RVTY ) Surpasses Q3 Earnings Estimates
Revvity (RVTY) delivered earnings and revenue surprises of +3.51% and -0.15%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Will RVTY Q3 Earnings Reflect Segmental Strength Amid Rising Demand?
RVTY's third-quarter results are likely to reflect strong performance in the Life Sciences segment. However, the Diagnostic segment is set to face challenges in China.
Revvity ( RVTY ) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
Get a deeper insight into the potential performance of Revvity (RVTY) for the quarter ended September 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Labcorp Holdings ( LH ) Reports Next Week: Wall Street Expects Earnings Growth
Labcorp (LH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's Driving the Market Sentiment Around Revvity Inc? - Revvity ( NYSE:RVTY )
Revvity Inc's ( NYSE:RVTY ) short interest as a percent of float has risen 4.26% since its last report. According to exchange reported data, there are now 7.30 million shares sold short, which is 9.05% of all regular shares that are available for trading.
Analysts Estimate Revvity ( RVTY ) to Report a Decline in Earnings: What to Look Out for
Revvity (RVTY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
RVTY Collaborates With Sanofi for Early Detection of Type 1 Diabetes
Revvity partners with Sanofi to launch a scalable diagnostic test for early T1D detection, expanding its reach beyond rare diseases.
Is Revvity Gaining or Losing Market Support? - Revvity ( NYSE:RVTY )
Revvity's RVTY short percent of float has risen 5.75% since its last report. The company recently reported that it has 6.23 million shares sold short, which is 7.73% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.3 days to cover their ...
Revvity Slashes Outlook As China Policy Deals Diagnostics Blow - Revvity ( NYSE:RVTY )
Revvity Q2 EPS of $1.18 beat the $1.14 estimate; revenue rose to $720.28 million, topping $710.71 million consensus. FY25 EPS guidance trimmed to $4.85-$4.95 from $4.90-$5.00 due to China DRG policy headwinds. Missed the rally? Learn exactly where the next leaders are emerging here. Revvity Inc.
RVTY Posts Q2 Earnings & Sales Beat, Raises '25 Sales View
Revvity's second-quarter results showcase strong growth in its Diagnostics business, along with recovery in Life Sciences segmental sales.
ATAI Life Sciences, Revvity And Other Big Stocks Moving Lower In Monday's Pre-Market Session - ATAI Life Sciences ( NASDAQ:ATAI ) , Cantor Equity Partners I ( NASDAQ:CEPO )
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 0.3% on Monday. Shares of ATAI Life Sciences NV ATAI fell sharply in pre-market trading after the company announced the Phase 2b trial of Inidascamine in patients with cognitive impairment associated with ...
Revvity Q2 Revenue Up 4 Percent
Revvity ( NYSE:RVTY ) , a global provider of life sciences and diagnostics tools, released its results for Q2 2025 on July 28, 2025. The company reported GAAP revenue of $720 million, surpassing Wall Street's GAAP estimate of $710.37 million.
Revvity ( RVTY ) Surpasses Q2 Earnings and Revenue Estimates
Revvity (RVTY) delivered earnings and revenue surprises of +3.51% and +1.27%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Why Revvity ( RVTY ) is Poised to Beat Earnings Estimates Again
Revvity (RVTY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Revvity Q2 Preview: Can Strong Segments Deliver an Earnings Beat?
RVTY is likely to see another earnings beat as Diagnostics momentum and Signals Software growth offset tariff headwinds.
Wall Street's Insights Into Key Metrics Ahead of Revvity ( RVTY ) Q2 Earnings
Beyond analysts' top-and-bottom-line estimates for Revvity (RVTY), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2025.
GeneDx Holdings Corp. ( WGS ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
GENEDX HOLDINGS (WGS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Revvity ( RVTY ) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Revvity (RVTY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Peering Into Revvity's Recent Short Interest - Revvity ( NYSE:RVTY )
Revvity's RVTY short percent of float has fallen 3.26% since its last report. The company recently reported that it has 5.63 million shares sold short, which is 6.83% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.65 days to cover their ...
Genomics Market to Hit US$66.8 Billion by 2029 with 9.4% CAGR | MarketsandMarkets™.
Delray Beach, FL, June 11, 2025 ( GLOBE NEWSWIRE ) -- The global genomics market, valued at US$42.4 billion in 2023, stood at US$42.6 billion in 2024 and is projected to advance at a resilient CAGR of 9.4% from 2024 to 2029, culminating in a forecasted valuation of US$66.8 billion by the end of ...
Pediatrix Medical Group ( MD ) Down 3.1% Since Last Earnings Report: Can It Rebound?
Pediatrix Medical Group (MD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
RVTY Stock Falls Despite the Latest Launch of Automated Instrument
Revvity unveils IDS i20, a fully automated immunodiagnostics platform designed to enhance lab efficiency and expand specialty testing.
Is the Market Bullish or Bearish on Revvity? - Revvity ( NYSE:RVTY )
Revvity's RVTY short percent of float has risen 8.41% since its last report. The company recently reported that it has 5.11 million shares sold short, which is 6.19% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.95 days to cover their ...
SynVivo Appoints Dr. Richard Eglen to Board of Directors
HUNTSVILLE, Ala., May 21, 2025 ( GLOBE NEWSWIRE ) -- SynVivo, a pioneering organ-on-chip company developing advanced microfluidic platforms that replicate human tissue microenvironments for drug discovery, today announced the appointment of Dr. Richard Eglen as a non-executive member of its ...
Company News for Apr 29, 2025
Companies In The News Are: DPZ, RVTY, OPRA, INMD.
RVTY Rises as Q1 Earnings & Sales Beat Estimates, '25 Sales View Up
Revvity's first-quarter results showcase strong growth in Diagnostics business, along with recovery in Life Sciences segmental sales.
Life Science Tools Maker Revvity Delivers Strong Q1 Earnings Despite Evolving Macroeconomic Backdrop - Revvity ( NYSE:RVTY )
Revvity Q1 sales hit $664.76 million, beating estimates, with adjusted EPS of $1.01, topping consensus of $0.95. 2025 sales outlook raised to $2.85 billion; adjusted EPS guidance affirmed at $4.90-$5.00. Feel unsure about the market's next move?
Revvity ( RVTY ) Beats Q1 Earnings and Revenue Estimates
Revvity (RVTY) delivered earnings and revenue surprises of 5.21% and 0.39%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Why Revvity ( RVTY ) Could Beat Earnings Estimates Again
Revvity (RVTY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Segmental Performance to Drive RVTY's Q1 Earnings: Is a Beat Likely?
RVTY's first-quarter results are likely to reflect decent performance in the Diagnostics segment. The Life Sciences segment is likely to have faced continued challenges in China.
Analysts Estimate Bausch + Lomb ( BLCO ) to Report a Decline in Earnings: What to Look Out for
Bausch + Lomb (BLCO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Revvity ( RVTY ) Q1 Earnings Expected to Decline
Revvity (RVTY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BD Seeks Potential Buyers for Life Sciences Business Division
Becton Dickinson is in preliminary talks to divest its $21 billion Life Sciences unit, exploring multiple options with major medtech players and diagnostics firms.
What's Going On With Revvity Stock Today? - Revvity ( NYSE:RVTY )
Revvity's Auto-Pure 2400 platform, approved by the FDA, enhances high-throughput latent TB testing with improved accuracy. RVTY stock rises after FDA approval, boosting lab productivity and supporting faster TB diagnosis and treatment. Feel unsure about the market's next move?
Here's Why You Should Retain Revvity Stock in Your Portfolio for Now
RVTY's strong product portfolio raises optimism about the stock.
Is Revvity Gaining or Losing Market Support? - Revvity ( NYSE:RVTY )
Revvity's RVTY short percent of float has risen 8.68% since its last report. The company recently reported that it has 5.18 million shares sold short, which is 5.76% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.51 days to cover their ...
Newborn Screening Market Size to Reach US$ 2.69 billion by 2031, Growing at a CAGR of 9.5%, Says The Insight Partners
US & Canada, March 24, 2025 ( GLOBE NEWSWIRE ) -- US & Canada, Mar, 24, 2025 ( GlobeNewswire ) -- According to a comprehensive report from The Insight Partners, "Newborn Screening Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report", The newborn ...
Revvity Stock Tumbles Despite Expanding Genomics England Alliance
RVTY expands its alliance with Genomics England to boost newborn genomic sequencing research, aiming to enhance early diagnosis and healthcare outcomes.
Molecular Infectious Disease Testing Market to Hit US$17.78 Billion by 2029 with 13.7% CAGR | MarketsandMarkets™.
Delray Beach, FL,, March 05, 2025 ( GLOBE NEWSWIRE ) -- The global Molecular Infectious Disease Testing market, valued at US$8.49 billion in 2023, is forecasted to grow at a robust CAGR of 13.7%, reaching US$9.37 billion in 2024 and an impressive US$17.78 billion by 2029.
What Does the Market Think About Revvity? - Revvity ( NYSE:RVTY )
Revvity's RVTY short percent of float has risen 15.51% since its last report. The company recently reported that it has 4.48 million shares sold short, which is 4.99% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.72 days to cover their ...
Do Options Traders Know Something About Revvity ( RVTY ) Stock We Don't?
Investors need to pay close attention to Revvity (RVTY) stock based on the movements in the options market lately.
RVTY Q4 Earnings Beat Estimates, Sales Miss, Segments Robust
Revvity's fourth-quarter results showcase strong growth in Diagnostics business, along with recovery in Life Sciences segmental sales.
Revvity ( RVTY ) Surpasses Q4 Earnings Estimates
Revvity (RVTY) delivered earnings and revenue surprises of 4.41% and 0.10%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Cencora ( COR ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Cencora (COR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Revvity Gears Up for Q4 Earnings: What's in the Offing?
RVTY's fourth-quarter results are likely to reflect decent performance in the Diagnostics segment. The Life Sciences segment is likely to have faced continued challenges in China.
Revvity ( RVTY ) Earnings Expected to Grow: Should You Buy?
Revvity (RVTY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
